Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy.

Authors: Burton, OT  Darling, AR  Zhou, JS  Noval-Rivas, M  Jones, TG  Gurish, MF  Chatila, TA  Oettgen, HC 
Citation: Burton OT, etal., Mucosal Immunol. 2013 Jul;6(4):740-50. doi: 10.1038/mi.2012.112. Epub 2012 Nov 14.
Pubmed: (View Article at PubMed) PMID:23149659
DOI: Full-text: DOI:10.1038/mi.2012.112

Interleukin (IL)-4 has critical roles in allergic disorders, including food hypersensitivity. The direct effects of the cytokine on the survival and function of mast cells, the key effectors of food anaphylaxis, have not been established. In this study, we demonstrate that IL-4 induces a marked intestinal mastocytosis in mice. This phenotype is reproduced in animals expressing Il4ralphaF709, an activating variant of the IL-4 receptor alpha-chain (IL-4Ralpha). Il4ralphaF709 mice exhibit enhanced anaphylactic reactions but unaltered physiological responses to vasoactive mediators. IL-4 induces Bcl-2 and Bcl-X(L) and enhances survival and stimulates proliferation in cultured bone marrow-derived mast cells (BMMC). These effects are STAT6 (signal transducer and activator of transcription factor 6)-dependent and are amplified in Il4ralphaF709 BMMC. In competitive bone marrow chimeras, Il4ralphaF709 mast cells display a substantial competitive advantage over wild-type mast cells, which, in turn, prevail over IL-4Ralpha(-)/(-) mast cells in populating the intestine, establishing a cell-intrinsic effect of IL-4 in intestinal mast cell homeostasis. Our results demonstrate that IL-4-signaling is a key determinant of mast cell expansion in food allergy.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 7829822
Created: 2014-01-28
Species: All species
Last Modified: 2014-01-28
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.